Evidence map›Paper›PMID 40006035›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Repeated-Dose Toxicity of Lauric Acid and Its Preventive Effect Against Tracheal Hyper-Responsiveness in Wistar Rats with Possible

Indyra Alencar Duarte Figueiredo, Alissa Maria de Oliveira Martins, Alexya Mikelle Teixeira Cavalcanti, Jayne Muniz Fernandes, Ludmila Emilly da Silva Gomes, Mateus Mendes Vieira, Gabriel Nunes Machado de Oliveira, Isabela Motta Felício, Lucas Nóbrega de Oliveira, Igor Gabriel da Silva Ramalho and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. EnhancedRSC advances · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Indyra Alencar Duarte FigueiredoLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Alissa Maria de Oliveira MartinsLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Alexya Mikelle Teixeira CavalcantiLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Jayne Muniz FernandesLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.ORCID 0000-0002-8686-8278
Ludmila Emilly da Silva GomesLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Mateus Mendes VieiraLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Gabriel Nunes Machado de OliveiraLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.ORCID 0000-0001-7014-7612
Isabela Motta FelícioLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Lucas Nóbrega de OliveiraLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Igor Gabriel da Silva RamalhoLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Natália Ferreira de SousaLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Luciana ScottiPrograma de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.ORCID 0000-0003-1866-4107
Marcus Tullius ScottiPrograma de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.ORCID 0000-0003-4863-8057
José Luiz de Brito AlvesDepartamento de Nutrição, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.ORCID 0000-0003-4696-3809
Margareth de Fátima Formiga Melo DinizPrograma de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Daniele Idalino Janebro XimenesDepartamento de Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal da Paraíba, Cidade Universitária, João Pessoa 58051-900, PB, Brazil.
Luiz Henrique César VasconcelosLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.
Fabiana de Andrade CavalcanteLaboratório de Farmacologia Funcional Prof. George Thomas, Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba, João Pessoa 58051-900, PB, Brazil.

Funding

Fundação de Apoio à Pesquisa do Estado da Paraíba 3158/2021
6 · The paper itself

Abstract

BACKGROUND/

objectivesLauric acid (LA), a medium-chain fatty acid, is a promising drug for asthma treatment. This study evaluated the toxicity of repeated doses and the effect of LA on pulmonary ventilation and tracheal reactivity in asthmatic Wistar rats and identified possible molecular targets of LA action

methodsThe rats were divided into control (CG) and LA-treated groups at 100 mg/kg (AL100G) for toxicity analysis. Pulmonary ventilation and tracheal reactivity were assessed in the control (CG), asthmatic (AG), asthmatic treated with LA at 25, 50, or 100 mg/kg (AAL25G, AAL50G, and AAL100G), and dexamethasone-treated groups (ADEXAG).

resultsThe results showed that LA at a dose of 100 mg/kg did not cause death or toxicity. A pulmonary ventilation analysis indicated that AG had reduced minute volume, which was prevented in AAL25G. LA at all doses prevented carbachol-induced tracheal hyper-responsiveness and reduced the relaxing effect of aminophylline, as observed in AG. An

conclusionsLA at 100 mg/kg has low toxicity, prevents hyper-responsiveness in an asthma model in rats, and acts as a multitarget compound with a good affinity for proteins related to airway hyper-responsiveness.

Indexed as

allergic inflammationdodecanoic acidmolecular dockingovalbuminpulmonary ventilationtracheal reactivity

Identifiers

PMID40006035
PMCPMC11859213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.